Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome

References

• Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Ehrmann D A. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223–1236
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47, Review
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505–522
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Iuorno M J, Nestler J E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325–340
   PubMed Web of Science ®Google Scholar
• Catrall F R, Healy D L. Long term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004; 18: 803–812
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Andrico S, Sartori F. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynaecol Endocrinol 2002; 16: 274–284
   Web of Science ®Google Scholar
• Hatch R, Rosenfield R M, Kim M H, Tredway D. Hirsutism: implications, etiology and management. Am J Obstet Gynecol 1981; 140: 815–830
   PubMed Web of Science ®Google Scholar
• Essah P A, Wickham E P, III, Nunley J R, Nestler J E. Dermatology of androgen-related disorders. Clin Dermatol 2006; 24: 289–298
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Nestler J E. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin. J Clin Endocrinol Metab 2006; 91: 22–24
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141–146
   PubMed Web of Science ®Google Scholar
• Adashi E Y, Resnick C E, D'Ercole A J, Svoboda M E, Van Wyk J J. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrinol Rev 1985; 6: 400–420
   PubMed Web of Science ®Google Scholar
• Barbieri R L, Makris A, Randall R W, Daniels G, Kistner R W, Ryan K J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904–910
   PubMed Web of Science ®Google Scholar
• Nestler J E, Powers L P, Matt D W, Steingold K A, Plymate S R, Rittmaster R S, Clore J N, Blackard W G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83–89
   PubMed Web of Science ®Google Scholar
• Farshchi H, Rane A, Love A, Kennedy R L. Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J Obstet Gynaecol 2007; 27: 762–773
   PubMedGoogle Scholar
• Nestler J E, Stovall D, Akhter N, Iuorno M J, Jakubowicz M J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209–215
   PubMed Web of Science ®Google Scholar
• Dunn C J, Peters D H. Metformin: a review of its pharmacological properties and therapeutic uses in non-insulin dependent diabetes. Drugs 1995; 49: 721–749
   PubMed Web of Science ®Google Scholar
• Saltiel A R. Second messengers of insulin action. Diabetes care 1990; 13: 244–256
   PubMed Web of Science ®Google Scholar
• Romero G, Larner J. Insulin mediators and the mechanism of insulin action. Adv Pharmacol 1993; 24: 21–50
   PubMedGoogle Scholar
• Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993; 90: 5924–5928
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Iuorno M J, Jakubowicz D J, Apridonidze T, He N, Nestler J E. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 242–249
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Diamanti-Kandarakis E, Ostlund R E, Apridonidze T, Iuorno M J, Nestler J E. Altered d-chiro-inositol urinary clearance in women with the polycystic ovary syndrome. Diabetes Care 2006b; 29: 300–305
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Eng J Med 1999; 340: 1314–1320
   PubMed Web of Science ®Google Scholar
• Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrinol Pract 2002; 8: 417–423
   PubMedGoogle Scholar
• Gerli S, Mignosa M, Di Renzo G C. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003; 7: 151–159
   PubMedGoogle Scholar
• Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of d-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Endocrinol Pract 2006; 72: 1310–1315
   Google Scholar
• Papaleo E, Unfer V, Baillargeon J P, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700–703
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Lanzoni C, Ricchieri F, Jasonni V M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139–144
   PubMed Web of Science ®Google Scholar
• Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008; 17: 579–582
   PubMed Web of Science ®Google Scholar
• Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher B F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function froma fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Martin K A, Chang R J, Ehrmann D A, Ibanez L, Lobo R A, Rosenfield R L, Shapiro J, Montori V M, Swiglo B A. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1105–1120
   PubMed Web of Science ®Google Scholar
• Shapiro J. Clinical practice. Hair loss in women. N Engl J Med 2007; 357: 1620–1630, [Comment in: N Engl J Med 2008;358:533;author reply 533]
   PubMed Web of Science ®Google Scholar
• Rosenfield R L. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 2001; 45: S095–S104
   PubMed Web of Science ®Google Scholar
• Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2008, in press
   PubMed Web of Science ®Google Scholar
• Futterweit W, Ryan G L. A patient's guide to PCOS. Henry Holt, New York 2006
   Google Scholar
• van Vloten W A, van Halesen C W, van Zuuren E J, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2–15
   PubMedGoogle Scholar
• Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2008, in press
   PubMed Web of Science ®Google Scholar
• Salley K E, Wickham E P, Cheang K I, Essah P A, Karjane N W, Nestler J E. Glucose intolerance in polycystic ovary syndrome. A position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92: 4546–4556
   PubMed Web of Science ®Google Scholar
• Nestler J E. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358: 47–54
   PubMed Web of Science ®Google Scholar
• Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 2003; 327: 951–957
   PubMed Web of Science ®Google Scholar
• Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocrinol Pract 2005; 11: 126–134
   PubMedGoogle Scholar
• Cheang K I, Baillargeon J P, Essah P A, Ostlund R E, Jr, Apridonize T, Islam L, Nestler J E. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008; 57: 1390–1397
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Nestler J E, Ostlund R E, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008; 23: 1439–1446
   PubMed Web of Science ®Google Scholar